Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine

References

• Chua GT, Xiong X, Choi EH, et al. COVID-19 in children across three Asian cosmopolitan regions. Emerg Microbes Infect. 2020;9:2588–2596.
   PubMed Web of Science ®Google Scholar
• Chua GT, Wong JSC, Lam I, et al. Clinical characteristics and transmission of COVID-19 in children and youths during 3 waves of outbreaks in Hong Kong. JAMA Netw Open. 2021;4:e218824.
   PubMed Web of Science ®Google Scholar
• Xiong X, Chua GT, Chi S, et al. A comparison between Chinese children infected with coronavirus disease-2019 and with severe acute respiratory syndrome 2003. J Pediatr. 2020;224:30–36.
   PubMed Web of Science ®Google Scholar
• Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and outcomes of US children and adolescents With multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 2021;325:1074–1087.
   PubMed Web of Science ®Google Scholar
• Hageman JR. Long COVID-19 or post-acute sequelae of SARS-CoV-2 infection in children, adolescents, and young adults. Pediatr Ann. 2021;50:e232–e233.
   PubMed Web of Science ®Google Scholar
• Chu VT, Yousaf AR, Chang K, et al. Household transmission of SARS-CoV-2 from children and adolescents. N Engl J Med. 2021;385:954–956.
   PubMed Web of Science ®Google Scholar
• Tso WWY, Wong RS, Tung KTS, et al. Vulnerability and resilience in children during the COVID-19 pandemic. Eur Child Adolesc Psychiatry. 2020;1–16. DOI:10.1007/s00787-020-01680-8.
   Web of Science ®Google Scholar
• Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386:35–46.
   PubMed Web of Science ®Google Scholar
• Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:803–812.
   PubMed Web of Science ®Google Scholar
• Reis BY, Barda N, Leshchinsky M, et al. Effectiveness of BNT162b2 vaccine against delta variant in adolescents. N Engl J Med. 2021;385:2101–2103.
   PubMed Web of Science ®Google Scholar
• Li XN, Huang Y, Wang W, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect. 2021;10:1751–1759.
   PubMed Web of Science ®Google Scholar
• Agency UHS. SARS-CoV-2 variants of concern and variants under investigation in England. Technical Briefing 32. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1042046/Technical_Briefing_32.pdf
   Google Scholar
• Lu L, Mok BW, Chen LL, et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin Infect Dis. 2021;ciab1041. DOI:10.1093/cid/ciab1041.
   Web of Science ®Google Scholar
• Zhang L, Li Q, Liang Z, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg Microbes Infect. 2022;11:1–5.
   PubMed Web of Science ®Google Scholar
• Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol. 2021;22:25–31.
   PubMed Web of Science ®Google Scholar
• Pierce CA, Preston-Hurlburt P, Dai Y, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Sci Transl Med. 2020;12:eabd5487.
   PubMed Web of Science ®Google Scholar
• Frenck RW J, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385:239–250.
   PubMed Web of Science ®Google Scholar
• Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:1645–1653.
   PubMed Web of Science ®Google Scholar
• Chua GT, Kwan MYW, Chui CSL, et al. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comirnaty vaccination. Clin Infect Dis. 2021;ciab989. DOI:10.1093/cid/ciab989.
   Web of Science ®Google Scholar
• Tsang HW, Chua GT, To KK, et al. Assessment of SARS-CoV-2 immunity in Convalescent children and adolescents. Front Immunol. 2021;12:797919.
   PubMed Web of Science ®Google Scholar
• Lu L, Chu AW, Zhang RR, et al. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. EBioMedicine. 2021;71:103544.
   PubMed Web of Science ®Google Scholar
• Chan WM, Ip JD, Chu AW, et al. Phylogenomic analysis of COVID-19 summer and winter outbreaks in Hong Kong: An observational study. Lancet Reg Health West Pac. 2021;10:100130.
   PubMedGoogle Scholar
• Dejnirattsiai W, Shaw RH, Supasa P, et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet. 2022;399:234–236.
   PubMed Web of Science ®Google Scholar
• Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2021. DOI:10.1038/s41586-021-04386-2.
   Web of Science ®Google Scholar
• Rossler A, Riepler L, Bante D, et al. SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and Convalescent persons. N Engl J Med. 2022:NEJMc2119236. DOI:10.1056/NEJMc2119236.
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50.
   PubMed Web of Science ®Google Scholar
• Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384:533–540.
   PubMed Web of Science ®Google Scholar
• Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385:2140–2149.
   PubMed Web of Science ®Google Scholar